Ex Vivo Assessment of Different Oral Anticoagulant Regimens on Pump Thrombosis in a HeartWare Ventricular Assist Device
- 1 July 2021
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation: Heart Failure
- Vol. 14 (7), 746-754
- https://doi.org/10.1161/circheartfailure.120.007231
Abstract
Background: In light of decreased intracranial hemorrhage with direct oral anticoagulants and concerns about their safety in continuous flow left ventricular assist devices, we conducted an ex vivo study of thrombus formation using multiple anticoagulation agents. Methods: A continuous flow left ventricular assist device (HeartWare ventricular assist device) hemocompatibility loop was run using human blood under 7 conditions: control (no anticoagulation or antiplatelet); in vitro addition of aspirin; in vitro addition of apixaban at low dose (equivalent 2.5 mg twice daily); addition of apixaban at high dose (equivalent 5 mg twice daily); patients on warfarin; patients on apixaban (5 mg twice daily); and patients on dabigatran (150 mg twice daily). The primary outcome was time to formation of intrapump thrombosis. Secondary outcomes were reduction in clotting times over 1 hour, hemolysis, reduced platelet aggregation, and von Willebrand activity. Results: Twenty-one runs were completed. Times to thrombosis in median (interquartile range) were control, 131 (127–134.5); in vitro aspirin, 124 (114.5–137); and patients on dabigatran, 131 (130.5–135.5) minutes, respectively. Times in patients on warfarin were, 137 (136.5–143.5); in vitro low-dose apixaban, 141 (138.5–142); and patients on apixaban, 140 (138–142.5) minutes, respectively. No thrombus formed in the in vitro high-dose apixaban group. There were no significant differences between the individual groups. When all apixaban groups were compared with nonapixaban groups, the time to thrombosis formation was significantly longer, 143 (137–150) versus 133.5 (128.5–140) minutes, P =0.02. There were similar changes in lactate dehydrogenase levels and other secondary end points. Conclusions: In an in vitro study of anticoagulation using human blood in a mock loop with a HeartWare HVAD, we demonstrated similar thrombosis times for apixaban and warfarin. Time to clotting was longer in the combined apixaban groups compared with combined other groups, but thrombosis times between individual groups were not significantly different.This publication has 25 references indexed in Scilit:
- Antithrombotic Therapy for VTE DiseaseSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2016
- Identification and Management of Pump Thrombus in the HeartWare Left Ventricular Assist Device SystemJACC: Heart Failure, 2015
- Dabigatran is Less Effective Than Warfarin at Attenuating Mechanical Heart Valve‐Induced Thrombin GenerationJournal of the American Heart Association, 2015
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014
- The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgeryExpert Review of Hematology, 2013
- Dabigatran versus Warfarin in Patients with Mechanical Heart ValvesThe New England Journal of Medicine, 2013
- New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysisGastroenterology, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- Dabigatran versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2009
- Bleeding Complications With Warfarin UseArchives of Internal Medicine, 2007